Maria Badillo
Overview
Explore the profile of Maria Badillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaulin C, Jain P, Nair R, Iyer S, Lee H, Fayad L, et al.
Leuk Lymphoma
. 2025 Jan;
1-5.
PMID: 39838574
No abstract available.
2.
Zhang S, Jiang V, Han G, Hao D, Lian J, Liu Y, et al.
Nat Commun
. 2024 Oct;
15(1):8668.
PMID: 39375332
No abstract available.
3.
Yan F, Jiang V, Jordan A, Che Y, Liu Y, Cai Q, et al.
Exp Hematol Oncol
. 2024 Feb;
13(1):14.
PMID: 38326887
Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton's tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy with dismal outcomes....
4.
Jiang V, Liu Y, Lian J, Huang S, Jordan A, Cai Q, et al.
J Clin Invest
. 2023 Jan;
133(3).
PMID: 36719376
Bruton's tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We...
5.
Wang M, Jain P, Zhao S, Lee H, Nastoupil L, Fayad L, et al.
Lancet Oncol
. 2022 Jan;
23(3):406-415.
PMID: 35074072
Background: Induction with ibrutinib and rituximab provides an opportunity to minimise chemotherapy exposure, because upfront use of these targeted therapies could result in remission without chemotherapy and allow for consolidation...
6.
Jain P, Zhao S, Lee H, Hill H, Ok C, Kanagal-Shamanna R, et al.
J Clin Oncol
. 2021 Nov;
40(2):202-212.
PMID: 34797699
Purpose: Most patients with mantle cell lymphoma (MCL) are older. In this study, we investigated the efficacy and safety of a chemotherapy-free combination with ibrutinib and rituximab (IR) in previously...
7.
Garay E, Serrano-Coll H, Rivero R, Gastelbondo B, Faccini-Martinez A, Berrocal J, et al.
Trans R Soc Trop Med Hyg
. 2021 Jun;
116(2):139-147.
PMID: 34185868
Background: Serological evaluation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an alternative that allows us to determine the prevalence and dynamics of this infection in populations. The goal...
8.
Zhang S, Jiang V, Han G, Hao D, Lian J, Liu Y, et al.
Nat Commun
. 2021 May;
12(1):2877.
PMID: 34001881
The mechanisms driving therapeutic resistance and poor outcomes of mantle cell lymphoma (MCL) are incompletely understood. We characterize the cellular and molecular heterogeneity within and across patients and delineate the...
9.
Lee H, Feng L, Oriabure O, Graham V, Chen W, Badillo M, et al.
Am J Hematol
. 2021 Apr;
96(7):E243-E246.
PMID: 33811767
No abstract available.
10.
Jain P, Kanagal-Shamanna R, Zhang S, Ok C, Navsaria L, Nastoupil L, et al.
Am J Hematol
. 2021 Jan;
96(5):E137-E140.
PMID: 33491779
No abstract available.